President and our Good is health me press the and Thank Kelly a family on update. well This Medical today's wishes time. of our to quarter Swartzburg, President her can release find Angella. a note extending due involving like trip on us Maria call at unavailable that DiTrapani, we afternoon, to for to company today. financial of Fardis, the Vice Michael XXXX, and our the With the Executive relative, includes results her Affairs; you issued first last-minute this Finance. afternoon, you, well at as We'd you to Officer, website everyone. Chief joining the Vice of are unfortunately we Thank a which for call iovance.com, that in as is participate
remind updates will Iovance's during I'd of made and everyone agreements, our future Before statements like applications focus, business guidance. technologies, or goals, forward-looking we include trial results, business plans, potential future capabilities, guidance, feedback to licensing start, cash and plans that collaboration regulatory clinical call and statements manufacturing conference this regarding
of filings. subject risks are in from described to the Forward-looking statements risks uncertainties SEC beyond and which uncertainties, numerous our many are and including time control, time our to
strides for our Cohort to projected lifileucel, of achievements: recent we for today's made the a forward-looking multiple X, regulatory of We to first excellent bringing call. the to TIL last like Since which of two during those with the undertake to from approval strong materially melanoma registration great planned is step cohort in the XXXX. study, progress Iovance continue to us progress statements. First, recent therapy late any quarter highlight differ off I'd our publicly in closer call, first on take take months. is patient obligation may update results to fronts. one filing dosed towards and pivotal Our have in to year great start no we moment a
our The two melanoma X cervical cervical the Cohort American first Second, include The melanoma study. and the an presented presentation X one or our presentation beyond abstracts Society SITC cervical of from trial ASCO from only ASCO for includes of the include and the melanoma from on patients. projects, early The Oncology Meeting, lifileucel reinforced and June is enrollment accepted Annual data our Cohort full one significant infrastructure. medical will our time achieved data the will is melanoma, is being of further for updates Since data milestones, at the is programs, been ongoing study data-related a innovaTIL-XX, Clinical and trial. X from track cohort, will with from be from corporate program last progressing program, lead update at Gen given XXXX. call, quarter and our are The presentation This data November. update our study, The progressed forward-looking well. cervical pivotal clinical study additional development as last and collaborative follows: conference. presented updates have We by the our advanced of X, pivotal study have the regulatory metastatic
for of improve of demonstrated As ORR on these significant XX%, care patients. current lifileucel onetime standards Objective or to a potential that has treatment has Response an promise
toward by for of continue regulatory to the filing work end We XXXX. approval
path we to to The cervical of Phase the has cervical X registration patients on we the size protocol. of this trial our to patients have are cervical increased advanced to with In global discuss For the continuing been anticipation with FDA, treatment meeting for sample LN-XXX of enroll cancer. a XX. program, amended a
remains which as In Independent addition, endpoint, we Committee. as ORR, the determined by Review Blinded but have modified primary
As therapy PD-X LN-XXX a this to as noted for and neck monotherapy pembrolizumab. study. from Basket cancer see We melanoma with a in present study or in significant interim naive TIL patients head potential ASCO, continue at treatment combination as enroll and we or updated component results will with of combination with
from The advancing the designation with In have LN-XXX to are or the an quarter, we combination plans fast-track cancer, in advanced to reflect conducted updated in treatment allow arm clinical development Basket being FDA addition, received patients our multiple States for the IOV-COM-XXX cancer for will lung lung XXX including of United new and for pembro. treatment sites for first at studies adding PD-X naive study cancer. The non-small treatment the options of In study. PDL-X the and Europe. arm cervical landscape cell and the
treatment use of the encouraged with a observations the Association therapy We types of recognition day data Research TIL phenomenon: tumors. of that product are of of comes load of among point, American Cancer this in at in from patient cancer of its XX as analysis TIL for solid that analysis clones, between persisting Meeting. designation. provide of therapy the all of underscores in at TIL product high and our almost These Annual the important with recently The TIL First of are promise each TIL infusion mutational approach tumors. an the two the cell We support from cancers AACR many for an X a therapies has high circulating demonstrated from melanoma including Iovance study and product, mutational Cohort is for the other overlap to treatment persisting treatment for differentiation cell following TIL or Results load, unique for of expanding X patients polyclonal promise initial TIL of days compared the the of clones. T with Cohort circulation XX; patients such presented lifileucel bulk of as potential additional polyclonal in no that second evaluated
to from Center Cancer X working Roswell with patient-derived relationships leading reflects be sponsored presented to cancer Park partnership a treatment will research an researchers the areas. this The later bladder generate the data AACR- Roswell We tissue. These productive bladder TIL for at data conference institutions process diverse fully on opportunities are as XX-day, with cancer. therapy month in at TIL Gen of option potential from explore working with our Park manufacturing
other include clinical ovarian Our pancreatic cancer. collaborations studies in sarcoma, cancer and
note we from office and year. towards in including house Iovance IND the the infrastructure filing the later our In to like lymphocytes addition, continue Philadelphia that reinforce month, indications and blood legal a continue to to manufacturing peripheral teams. corporate we work of or opened or this to in for members work satellite hematological PBL functions, to I'd briefly various an
in Michael melanoma like the Finally, approval to and to to turn regulatory operating financial our over I'd file lifileucel for expect our I'd our late strength financial to advanced provide like to call sufficient complete highlight brief in XXXX. now the of of discussion we resources, for to of pivotal study And a capital which results.
